Kelsey Lucerne's questions to Atea Pharmaceuticals Inc (AVIR) leadership • Q2 2025
Question
Kelsey Lucerne from William Blair & Company inquired about the enrollment progress and investigator enthusiasm for the Phase III C BEYOND and C FORWARD trials.
Answer
Chief Medical Officer Dr. Arantxa Horga confirmed that enrollment is on track, with C BEYOND progressing faster due to quicker North American regulatory approvals. She noted that the steady enrollment reflects significant investigator enthusiasm and a strong patient value proposition.